304
Participants
Start Date
February 28, 2024
Primary Completion Date
June 17, 2025
Study Completion Date
June 17, 2025
MK-1200
IV Infusion
Antiemetic
One or more prophylactic antiemetic(s) (e.g. 5-HT3 receptor antagonists, dexamethasone, neurokinin-1 receptor antagonists, etc.) may be selected based on previous response of participants to antiemetic medications and individual factors, and will be administered per approved product label prior to MK-1200 infusion
The Alfred Hospital ( Site 0103), Melbourne
University of Virginia Health System-Hematology-Oncology ( Site 0009), Charlottesville
The University of Louisville, James Graham Brown Cancer Center ( Site 0004), Louisville
START Midwest ( Site 0014), Grand Rapids
South Texas Accelerated Research Therapeutics (START) ( Site 0005), San Antonio
START Mountain Region ( Site 0015), West Valley City
Beijing Cancer hospital-Digestive Oncology ( Site 0401), Beijing
First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0415), Huai'an
Fujian Cancer Hospital-oncology department ( Site 0409), Fuzhou
Rambam Health Care Campus-Oncology Division ( Site 0602), Haifa
Rabin Medical Center-Oncology ( Site 0603), Petah Tikva
Sheba Medical Center ( Site 0605), Ramat Gan
Sourasky Medical Center ( Site 0601), Tel Aviv
Bradfordhill-Clinical Area ( Site 0301), Santiago
Hadassah Medical Center ( Site 0604), Jerusalem
Samsung Medical Center-Division of Hematology/Oncology ( Site 1003), Seoul
Merck Sharp & Dohme LLC
INDUSTRY